Literature DB >> 26123879

Anaerobic blood culture isolates in a Norwegian university hospital: identification by MALDI-TOF MS vs 16S rRNA sequencing and antimicrobial susceptibility profiles.

Nina Handal1, Silje Bakken Jørgensen1, Hege Smith Tunsjø2, Bjørn Odd Johnsen1, Truls Michael Leegaard1.   

Abstract

We investigated 197 anaerobic isolates recovered from blood cultures in the period 2009-2013. The isolates included were Bacteroides spp., Clostridium spp., Prevotella spp., Fusobacterium spp. and Gram-positive anaerobic cocci (GPAC). Identification results by MALDI-TOF MS were compared to those obtained by 16S rRNA sequencing, and the MICs of benzylpenicillin, clindamycin, piperacillin-tazobactam, meropenem and metronidazole were determined by Etests. The MALDI-TOF MS correctly identified 94.9% of the anaerobes to the genus level, and 86.8% to the species level, with errors mainly among the non-fragilis Bacteroides spp. and GPAC. About 73.3% of the isolates were non-susceptible to penicillin, mainly due to high resistance rates in the Bacteroides spp. (99.2%) and Prevotella spp. (69.2%). About 18.5% of the isolates were clindamycin resistant. Piperacillin-tazobactam had an excellent activity against all anaerobes except the non-fragilis Bacteroides spp., of which 43.8% were non-susceptible. The clinical significance of such a high resistance rate is unclear. Meropenem and metronidazole were the most active antibiotics, with 96.9% and 97.9% of the isolates being susceptible.
© 2015 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Anaerobic bacteria; MALDI-TOF; antimicrobial susceptibility

Mesh:

Substances:

Year:  2015        PMID: 26123879     DOI: 10.1111/apm.12410

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  1 in total

1.  Application of MALDI-TOF MS to rapid identification of anaerobic bacteria.

Authors:  Ying Li; Mingzhu Shan; Zuobin Zhu; Xuhua Mao; Mingju Yan; Ying Chen; Qiuju Zhu; Hongchun Li; Bing Gu
Journal:  BMC Infect Dis       Date:  2019-11-07       Impact factor: 3.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.